Anti Viral, Cancer, Syndrom

From Here toanz: Bothonison200 and AURA resolve mutations that cause cancer

and 10,000 people are diagnosed with prostate cancer each year.
When diagnosed, about half of patients will experience metastatic disease, a form of the disease that affects organs and organs in the environment and has few effective treatments.
Treatment eligibility considerations for AURA cancer include those patients who are cancer-free initially and develop recurrent cancers.
“AURA is a breakthrough cancer treatment that provides both new and improved benefits to families and patients affected by recurrent bladder cancer,” said Scott Mieloski, Clinical Director of the Division of Cancer Medicine at Dana-Farber/Boston Children’s Cancer and Blood Diseases Institute and lead researcher for the pioneers trial.
All patients were followed for 6 months.
Mieloski is the driving force behind the study, as he controls the clinical flow and external support of the research team,” said Panagis Galiatsatos, MD, director of the CRC Program in Prostate Cancer, Cancer and Urologic Oncology at Dana-Farber/Boston Children’s.

Anti Viral

Koch-controlled Initiative tracks progress made in prostate cancer education

Charles Easley, Sr., known for his pioneering work that led to the identification of prostatic hyperstimulation syndrome (PSS), has started a six-month initiative that aims to track and improve the pace of research progress in prostate cancer education. The initiative is funded through $439,360 in funding from Koch National Institute of Child Health (K-NIC), part of K-State’s Research, Practice, and…

Continue Reading